Diagnostics, point-of-care, and pharmaceutical research will drive the rapidly-expanding microfluidic products industry to a potential value of $23B by 2022. What will trigger the next growth spurt?
- Coverage of all major trends and evolutions in the microfluidics industry and markets
- Updated market data and forecasts to 2022, in value and units for microfluidic devices and products
- Analysis of strategic moves (M&A, collaborations, fundraising) since 2015
- Top microfluidic players/foundries – 2016 rankings
- Updated information, by microfluidic market segment
- Review of new, promising applications for microfluidic technologies
- Current supply chain
KEY FEATURES OF THE REPORT
- Market evolution and maturation: analyzing the key events from the last two years, including M&A, innovative product launches, fundraising, and collaborations
- Detailed 2017 – 2022 market data and forecasts by market segment, for the microfluidic device and microfluidic product markets
- Thorough analysis of the materials and manufacturing processes across different microfluidic segments
- Comprehensive supply chain analysis
OBJECTIVES OF THE REPORT
This report’s objectives are to:
- This new Yole Développement report provides a complete analysis of microfluidic device/product applications, markets, and technologies:
- New major trends and evolutions in the microfluidics industry and markets
- Analysis of strategic moves since 2015
- New microfluidics players/foundries – 2016 ranking
- Updated market data and forecast up to 2022, in value and units for microfluidic devices and products
- Current supply chain
- In order to better understand how value is spread across the supply chain, this report covers both the microfluidics device and product markets
- Market trends and main players are presented for each product category, via an exclusive market segmentation
- An exhaustive analysis is provided of the materials and manufacturing processes in various microfluidic segments
- Also offered is a presentation of new, promising applications for microfluidic technologies
Table of contents
Executive Summary p.8
Status of the microfluidics market p.50
- What’s the next killer application?
- Supply chain models
- The future of microfluidic foundries
- Towards design standards?
- Two types of diagnostics players
- New collaborations since 2015
- Fundraising since 2015
- Mergers and acquisitions since 2015
- Strategic moves analysis
- Stock market
- Patent landscape
- Razor and razor-blade business model
- Detection methods
Market segmentation p.92
Microfluidics market p.96
- What we got wrong and why
- Products market (volume, value, dynamics)
- Devices market (value, dynamics)
- Market shares
- Pure-fabs vs. The hidden in-house market
Microfluidic segments description p.115
- Segment 1: Clinical and veterinary tests
- Segment 2: Point of care testing
- Segment 3: Industrial, environmental, agro-food
- Segment 4: Life science research
- Segment 5: Micro-reactor and flow chemistry
- Segment 6: Analytical devices
- Segment 7: Drug delivery
- Segment 8: Accurate dispensing
- Segment 9: Flow control
Emerging applications p.200
- Liquid biopsy
- Electronic cooling
- Liquid Lenses
Focus on digital microfluidics p.212
Microfluidic technologies p.218
- Material mix analysis
- Manufacturing processes
Microfluidics supply chain p.234
Summary and conclusions p.242
MICROFLUIDIC TECHNOLOGIES HAVE FINALLY FOUND SWEET SPOTS, AND THERE ARE ALREADY CREDIBLE OPTIONS FOR THE NEXT UPSURGE
Microfluidic technologies have been around for a while, but only in the last few years have certain applications started benefiting from microfluidic breakthroughs. First, next-generation sequencing (NGS) found new possibilities enabled by microfluidics; next, in 2014/2015, point-of-care (PoC) testing (especially molecular diagnostics for decentralized use) began reaping microfluidic technologies’ full benefits. These applications are still driving the microfluidics industry’s growth and structure.
In this Status of the Microfluidics Industry report, Yole Développement announces a $2.5B microfluidic device market in 2017 and forecasts a $5.8B market by 2022 (CAGR2017-2022 = 18%). From microfluidic devices like manufactured chips, delivery tools, and dispensers, microfluidic-based products (i.e. diagnostic tests with reagents, vaccines, and cartridges) are provided to end-users, offering numerous possibilities.
The industry’s growth is not surprising, given the high demand from end-users for increasingly automated, integrated, miniaturized solutions. And the microfluidics industry could experience additional growth booms in the next few years. In particular, cancer diagnostics, treatment planning, and follow-up look extremely promising with the increased use of microfluidic technologies at sample preparation level (isolation of circulating tumor cells and DNA in liquid biopsies) and at diagnostics level (molecular diagnostics for oncology for the analysis of these cells and DNA molecules). Organs-on-chips is another microfluidics application with the potential to become a multi-billion-dollar market, enabling more predictive models for drug and compound testing. There is no doubt these emerging applications will drive the market’s continuous growth over the next decade, especially with a myriad of startups emerging and proposing innovative microfluidic solutions to solve today’s and tomorrow’s major issues.
LARGE DIAGNOSTICS COMPANIES ARE RACING TO ACQUIRE THE MOST PROMISING MICROFLUIDIC COMPANIES. MEANWHILE, MORE AND MORE STARTUPS EMERGE.
Alongside these innovative startups walk the diagnostics giants. They usually propose a few, often successful microfluidic solutions within their immense portfolio: Abbott, Alere, bioMérieux, and Roche have all witnessed growth in at least one of their segments, driven by a microfluidic solution. These success stories result from a solid industry structuration over the past few years: among the numerous companies developing microfluidic-based products, the most promising ones are often acquired by the large diagnostics companies. This was the case for some of molecular diagnostics’ most innovative players: IQuum and BioFire, and more recently Cepheid and Nanosphere, were all acquired by much larger companies. In this context, Yole’s analysts have identified $25B in M&A across the microfluidics industry since 2015. This has created a virtuous circle: the most promising/most successful startups are acquired or become large players themselves, and investors are eager to put money into the ever-growing number of newcomers leveraging microfluidic technologies and know-how.
THE INDUSTRY’S SWIFT MATURATION HAS PROFOUNDLY IMPACTED THE ENTIRE SUPPLY CHAIN
Microfluidic technologies’ maturation and their increased use within the industry has impacted supply chain structure. Which diagnostics companies are producing their microfluidic devices in-house, which ones are outsourcing, and why? What is the cost of goods sold? Yole’s analysts have investigated these critical points, and their findings are revealed in this report.
Cost pressure is often very high for microfluidic device manufacturers trying to diversify their capabilities in order to generate higher value for their customers. Back-end processing, materials combination and reagent deposition are the points of improvement, rather than manufacturing processes, which have not changed much recently. Depending on the application, different materials are used: polymer, glass, and silicon devices have different properties and are rarely produced by the same players. Low-cost diagnostics disposables are made of polymer, whereas glass and silicon are used in higher-end applications where superior precision and quality are required.
10x Genomics, 3M, Abaxis, Abbott, Advanced Liquid Logic, Affymetrix, AGC, Agilent Technologies, Alere, Alfa Laval, Aline, Alza, Alzet, Angle, Apogee MEMS, Applied Biosystems, ARaymond Life, Arrayjet, A-Star, Ativa, Atlas Genetics, Axxicon, Axxin, Azbil, Baebies, Bartels Mikrotechnik, Bayer, BD, Beckman Coulter, Beijing Genomics Institute, Biocartis, BioFire Diagnostics, BioFluidix, BioMensio, bioMérieux, Bio-Rad, Biotechne, Boehringer Ingelheim, Bronkhorst, Brooks, Burkert, Caliper, Cambridge Consultants, CapitalBio Technology, Capsum, Carbo Analytics, CDA, CellSearch, Celsee, Cepheid, Cetoni, CG.TEC, Chemtrix, ChipCare, Corium, Corning, Crospon, Curiox, Cytena, Daktari Diagnostics, Danaher, DARPA, Debiopharm, Debiotech, Denz Biomedical, DiaSorin, Dimatix, DNA Electronics, Dolomite, Draper, Dublin City University, DuPont, Durect, EKF, Eksigent, Elveflow, Emulate, EnablingMNT, Enplas, Epigem, ETH Zürich, Etta Healthcare, Fast Track Diagnostics, Fluidigm, Fluigent, Focus Diagnostics, Fralock, Fraunhofer, Freescale, Future Chemistry, GE, Genalyte, Genapsys, GeneFluidics, GenePOC, GenMark Diagnostics, Gilson, Great Basin Scientific, Gyros, Hamilton, Helvoet, HNP Microsystems, Honeywell, HP, IBM Research, IDEX, Illumina, IMT, Imtek, Invenios, Invetech, InZign, Ion Torrent, IQuum, iX-Factory, Johnson & Johnson, Kapplex, Klearia, Kloehn, Kumetrix, Labcyte, LabSmith, LeukoDx, Life Technologies, LionIX, Little Things Factory, Lonza, Luminex, LUT, Malema, Medimate, Medspray, Medtronic, Menarini, Micralyne, microDrop, Microfluidic ChipShop, Microglass Chemtech, microLiquid, Micronics, Micronit, miniFab, Miroculus, MyCartis, Mylife Technologies, Nabsys, NanoBiosciences Nanocellect, NanoMR, NanoPass, Nanosphere, NASA, Norgren, Nortis, Omron, OndaVia, OPKO Diagnostics, Ovagene, Oxford Nanopore, Pacific Biosciences, Pall Corporation, PerkinElmer, Pfizer, Philips, PlanOptik, POC, Porter, PositiveID, RainDance, RedShift, Rheonix, Roche, Rogers Corporation, Rqmicro, Samsung, Savyon Diagnostics, Schlumberger, Schott, Scienion, Sciex, Screen Holdings, Sensirion, SensoDx, Seyonic, Shimadzu, Siemens, Sigma Aldrich, Silex Microsystems, Silicon Biosystems, Scandinavian Micro Biodevices, Sony DADC, Sphere Fluidics, STMicroelectronics, Stratec, Syntics, Takara, Takasago, TDK, TearLab, Tecan, Tecnisco, Telechem, Teledyne Dalsa, Thalesnano, The Lee Company, Thermo Fisher Scientific, ThinXXS, Translume, Tronics Microsystems, TSMC, TTP Labtech, TTP Group, Two Pore Guys, uFuidix, Valcor, Vaxxas, Vortex Biosciences, WaferGen Biosystems, Waters, Weidmann Plastics, Xaar, YMC, Zephyrus Biosciences, z-microsystems, Zoetis, Zosano, Zurich Instruments… and more
Related Reports & Monitors
Nano-Imprint Technology Trends for Semiconductor Applications 2019
Market & Technology
X-Ray Detectors for Medical, Industrial and Security Applications 2019
Market & Technology
Need to discuss?
We are open for discussionContact us